Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
|Videos|August 9, 2016
Mastectomy Vs Breast Conservation in Surgical Management of Breast Cancer
Author(s)Eleftherios P. Mamounas, MD
Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, compares mastectomy with breast conservation in the surgical management of breast cancer.
Advertisement
Advertisement
Related to this article
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
Durability of PFS and OS Benefit vs. Historical Control
5